Anti-HER2 treatment and breast cancer: State of the art, recent patents, and new strategies

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 1, 2009, Pages 9-18

  Daniele, Lorenzo ^a   Sapino, Anna ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; HER2; Target therapies

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ADENOVIRUS VECTOR; BIOTIN; CANCER VACCINE; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DEFOROLIMUS; E75; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EVEROLIMUS; GEFITINIB; GSK 572016; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MUCIN 4; OMITARG; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLASMID VECTOR; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; IMMUNOTHERAPY; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; BREAST TUMOR; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; FEMALE; GENETICS; PROTEIN TERTIARY STRUCTURE;

BREAST NEOPLASMS; DIMERIZATION; FEMALE; HUMANS; PATENTS AS TOPIC; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RNA INTERFERENCE;

EID: 62749160039     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209787002489     Document Type: Review

References (127)

1. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230(4730): 132-139.
2. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291(16): 1972-1977.
3. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5(1): 63-69.
4. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 Suppl 2: 1-13.
5. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5(5): 341-354.
6. Ricci A, Lanfrancone L, Chiari R, et al. Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene 1995; 11(8):1519-1529.
7. Bentires-Alj M, Gil SG, Chan R, et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 2006; 12(1):114-121.
8. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994; 13(12): 2831-2841.
9. Tan M, Yao J, Yu JD. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997; 57(6): 1199-1205.
10. Emlet DR, Brown KA, Kociban DL, et al. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007; 6(10): 2664-2674.
11. Ali SM, Leitzel K, Chinchilli VM, et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002; 48(8): 1314-1320.
12. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999; 59(6): 1196-1201.
13. Saez R, Molina A, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 2: 424-431.
14. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5(7): 953-962.
15. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol 2001; 1: 9-13.
16. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290(5803): 261-264.
17. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312(5994): 513-516.
18. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229(4717): 976-978.
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177-182.
20. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16(6): 413-428.
21. Press MF, Bernstein L,. Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15(8): 2894-2904.
22. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93(1): 3-11.
23. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25(1): 118-145.
24. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19(10): 2714-2721.
25. Bieche I, Onody P. Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999; 45: 1148-1156.
26. Pawlowski V, Revillion F, Hornez L, Peyrat JP. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer. Cancer Detect Prev 2000; 24(3): 212-223.
27. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003; 9(7): 2406-2415.
28. Mackay A, Jones C, Dexter T, et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003; 22(17): 2680-2688.
29. Kauraniemi P, Barlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001; 61(22): 8235-8240.
30. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4(7): 844-847.
31. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80(12): 1943-1949.
32. Gancberg D, Di Leo A, Rouas G, et al. Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol 2002; 55(4): 315-317.
33. Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES. Evaluation of HER-2/ neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 2003; 34(4): 362-368.
34. Muller V, Thomssen C, Karakas C, et al. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers 2003; 18(1):13-20.
35. Sapino A, Marchio C, Senetta R, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 2006; 449(3): 288-296.
36. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421(6924): 756-760.
37. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16(8): 2659-2671.
38. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
39. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-1684.
40. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-792.
41. Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9(3): 1165-1172.
42. Tokuda Y, Ohnishi Y, Shimamura K, et al. in vitro and in vivo Anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 1996; 73(11): 1362-1365.
43. Le XF, Pruefer F, Bast RC Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005; 4(1): 87-95.
44. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70.
45. Guzi, T. J., Paruch, K., Dwyer, M. P., Doll, R. J., Girijavallabhan, V. M., Mallams, A., Alvarez, C. S., Keertikar, K. M., Rivera, J., Chan, T., Madison, V. S., Fischmann, T. O., Dillard, Lawrence. W., Tran, V. D., He, Z., James, R. A., Park, H., Paradkar, V. M., Hobbs, D. W., Kirschmeier, P., Bannerji, R.: US20080050384 (2008).
46. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14(3): 737-744.
47. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17(9): 2639-2648.
48. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3): 719-726.
49. Pegram MD. Docetaxel and herceptin: Foundation for future strategies. Oncologist 2001; 6 Suppl 3: 22-25.
50. Tedesco K, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 2004; 22(6): 1071-1077.
51. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21(15): 2889-2895.
52. O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2003; 30(2 Suppl 3): 22-26.
53. Sledge GW Jr. Gemcitabine combined with paclitaxel or paclitaxel/ trastuzumab in metastatic breast cancer. Semin Oncol 2003; 30(2 Suppl 3): 19-21.
54. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 1992; 89(13): 5867-5871.
55. Allan SM, Dean C, Fernando I, et al. Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. Br J Cancer 1993; 67(4): 706-712.
56. Rosenblum MG, Horn SA, Cheung LH. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor. Int J Cancer 2000; 88(2): p267-273.
57. Rosenblum MG, Shawver LK, Marks JW, et al. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro Cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 1999; 5(4): p865-874.
58. Pluckthun, A., Honegger, A., Willuda, J.:US20087341722 (2008).
59. Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C. Bispecific HER2 × CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 1995; 74(2): 185-192.
60. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I. A human umor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 1993; 53(1): 94-100.
61. Weiner LM, Holmes M, Richeson A, et al. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 1993; 151(5): 2877-2886.
62. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93(24):1852-1857.
63. Nahta, R., Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64(11): 3981-3986.
64. Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13(16): 4909-4919.
65. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6(2): 117-127.
66. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005; 65(2): 473-482.
67. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12(4): 395-402.
68. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99(8): 628-638.
69. Anido J, Scaltriti M, Bech-Serra JJ, et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006; 25(13): 3234-3244.
70. Bussolati G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A. A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 2005; 92(7): 1261-1267.
71. Sapino A, Montemurro F, Marchio C, et al. Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: An hypothesis-generating study. Ann Oncol 2007; 18(12): 1963-1968.
72. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004; 17(5): 455-462.
73. Cho, H. S., Daniel, T. O., Wilson, T. E., Cujec, T. P., Tian, F., Hays, A., Kimmel, B. E., Lillian, H.: US20080050374 (2008).
74. Pupa SM, Bufalino R, Invernizzi RM, et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996; 14(1): 85-94.
75. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54(1): 16-20.
76. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15(11): 3363-3367.
77. Pupa SM, Menard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993; 53(24): 5864-5866.
78. Kiessling R, Wei WZ, Herrmann F, et al. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002; 85: 101-144.
79. Yip YL, Ward RL. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 2002; 50(11): 569-587.
80. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58(21): 4902-4908.
81. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8(5): 1014-1018.
82. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002; 8(11): 3407-3418.
83. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96(9): 3102-8.
84. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002; 8(11): 3394-3400.
85. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20(11): 2624-2632.
86. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5(6): 1289-1297.
87. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181(6): 2109-2117.
88. Avigan D, Vasir B., Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10(14): 4699-4708.
89. Peoples GE, Holmes PJ, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14(3): 797-803.
90. Holmes JP, Gates JD, Benavides LC, et al., Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008; 113(7): 1666-1675.
91. Aurisicchio, L., Ciliberto, G., La Monica N.: WO2008012237 (2008).
92. Koltermann, A.: WO2008000517 (2008).
93. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006; 55(6): 717-727.
94. Franklin MC, Carey, KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5(4): 317-328.
95. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50(5): 1550-1558.
96. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64(7): 2343-2346.
97. Agus DB, Gordon, MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23(11): 2534-2543.
98. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24(26): 4324-4332.
99. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007; 99(9): 694-705.
100. Amler, L. C., Moecks, J., Rabbee N., Strauss, A.: US200820080038271 ( 2008).
101. Wallasch C, Weiss FU, Niederfellner G, et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995; 14(17): 4267-4275.
102. Singer, E., Landgraf, R., Slamon, D., Eisenberg, D.: US20087314916 ( 2008).
103. Pienkos, P. T., Monticello, D. J.: WO2008005983 (2008).
104. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 2001: 61(19): 7196-7203.
105. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J 1996; 15(2): 254-264.
106. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17(12):3385-3397.
107. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006: 66(3):1630-1639.
108. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23(23): 5305-5313.
109. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355(26): 2733-2743.
110. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64(11): 3958-3965.
111. Wong KK, Fracasso PM, Bukowski RM. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. J Clin Oncol 2006; 24(suppl)(125s): Abstract 3018.
112. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 2004; 5(12): 1165-1170.
113. Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003; 2(10): 971-984.
114. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study. J Clin Oncol 2007; 25(34): 5410-5417.
115. Bali P, George P, Cohen P, et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004; 10(15): 4991-4997.
116. Burnie, J. P., Matthews, R., Carter T.: US20080038267 (2008).
117. Aftab, D. T., Laird, D. A., Lamb, P., Martini, J.A.:WO2008021389 ( 2008).
118. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19(56): 6680-6686.
119. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23(23): 5314-5322.
120. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26(10): 1588-1595.
121. Elit L. Drug evaluation: AP-23573: An mTOR inhibitor for the treatment of cancer. IDrugs 2006; 9(9): 636-644.
122. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002; 62(11): 3151-3158.
123. Elbashir SM., Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411(6836): 494-498.
124. Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108(1): 71-77.
125. Yang GKQ, Cai, JA, Thompson-Lanza RC, Bast Jr, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004; 279(6): 4339-4345.
126. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004; 18(5): 1007-1021.
127. Friess, T., Hasmann, M., Scheuer, W.: US20080050385 (2008).